OZEM
Roundhill Glp-1 & Weight Loss ETF
Price Chart
Latest Quote
$32.87
-0.64 (-1.91%)
Current Price
| Previous Close | $33.51 |
| Open | $33.06 |
| Day High | $33.06 |
| Day Low | $32.70 |
| Volume | 7,459 |
Fund Information
| Quarterly Dividend / Yield | N/A / 1.29% |
| Net Assets | $61.38M |
| Expense Ratio | 0.59% |
| Category | Health |
| Fund Family | Roundhill Investments |
| Net Asset Value | $34.12 |
| Premium/Discount | -3.66% |
| Quarterly Dividend Yield | 1.29% |
| P/E Ratio | 14.50 |
| Exchange | NGM |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $33.37 |
| SMA50 | $32.82 |
| SMA200 | $32.74 |
| RSI | 38.98 |
| ATR | 0.5689 |
| Rel Volume | 0.39 |
Performance History
| Week | -2.76% |
| Month | +1.10% |
| Quarter | +3.51% |
| 6 Months | -3.00% |
| YTD | -4.26% |
| Year | +28.82% |
| 10 Years | +31.39% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-31 | $32.88 | 7,500 |
| 2026-08-27 | $34.10 | 7,300 |
| 2026-08-26 | $34.17 | 8,400 |
| 2026-08-25 | $34.26 | 8,800 |
| 2026-08-24 | $33.86 | 21,000 |
| 2026-08-21 | $33.81 | 15,900 |
| 2026-08-20 | $33.74 | 9,500 |
| 2026-08-19 | $34.16 | 17,700 |
| 2026-08-18 | $33.16 | 30,700 |
| 2026-08-17 | $33.02 | 48,300 |
| 2026-08-14 | $33.03 | 15,200 |
| 2026-08-13 | $33.47 | 12,800 |
| 2026-08-12 | $33.57 | 6,700 |
| 2026-08-11 | $33.68 | 17,600 |
| 2026-08-10 | $33.82 | 18,100 |
| 2026-08-07 | $33.65 | 10,900 |
| 2026-08-06 | $32.86 | 12,600 |
| 2026-08-05 | $32.46 | 68,400 |
| 2026-08-04 | $31.91 | 22,500 |
| 2026-08-03 | $31.70 | 26,200 |
About Roundhill Glp-1 & Weight Loss ETF
The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset. The fund is non-diversified.
📰 Latest News
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Zacks • 2026-07-01T12:13:00Z
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
MarketBeat • 2026-06-20T12:45:00Z
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Zacks • 2026-06-10T16:00:00Z
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Zacks • 2026-05-19T18:27:00Z
Scoring 2 Million Prescriptions, Novo’s GLP-1 Pill Crushes Expectations
The Daily Upside • 2026-05-07T04:01:00Z
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
MarketBeat • 2026-04-17T15:20:00Z
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
Zacks • 2026-03-23T15:27:00Z
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Zacks • 2026-02-04T14:30:00Z
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
MarketBeat • 2026-01-19T20:23:00Z
2 under-the-radar ETFs retail investors should jump on
Yahoo Finance Video • 2026-01-07T11:00:38Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.